Tag: IGM

ADC Therapeutics Announces Updated LOTIS-2 Results

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European…

Continue Reading ADC Therapeutics Announces Updated LOTIS-2 Results

ADC Therapeutics (ADCT) Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA in R/R DLBCL

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will…

Continue Reading ADC Therapeutics (ADCT) Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA in R/R DLBCL

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023. First Quarter & Subsequent Highlights Met…

Continue Reading Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

HEALTH EFFECTS – Toxicological Profile for Phosphate Ester Flame Retardants

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects)….

Continue Reading HEALTH EFFECTS – Toxicological Profile for Phosphate Ester Flame Retardants

TG Therapeutics Announces Presentation of Data from the

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. A link…

Continue Reading TG Therapeutics Announces Presentation of Data from the

2023-06-02 | NDAQ:TGTX | Press Release

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting….

Continue Reading 2023-06-02 | NDAQ:TGTX | Press Release

2023-05-31 | NDAQ:ARDS | Press Release

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care…

Continue Reading 2023-05-31 | NDAQ:ARDS | Press Release

TG Therapeutics (TGTX) Announces Data from ULTIMATE I & II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at CMSC

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS),…

Continue Reading TG Therapeutics (TGTX) Announces Data from ULTIMATE I & II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at CMSC

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care…

Continue Reading Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Introduction Human immunodeficiency virus (HIV) infection is associated with an increased risk of hematological malignancy. Lymphoid neoplasms, particularly non-Hodgkin lymphoma, are the main hematologic malignancies that occur more frequently in connection with HIV infection non-Hodgkin lymphoma (NHL).1 Lymphomas are neoplastic lesions of the lymphoid system. According to World Health Organization…

Continue Reading Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies | BMC Infectious Diseases

Characteristics of included studies Based on our search, we retrieved 1700 citations. After removing duplicates, a total of 1250 articles were screened based on title and abstract. Furthermore, the hand-searching of other studies revealed 7 studies that met the inclusion criteria and were included after assessing their full texts. Overall,…

Continue Reading Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies | BMC Infectious Diseases

Gene Editing of Primary Rhesus Macaque B Cells

We present a method for culturing and gene editing primary rhesus macaque B cells using CRISPR/Cas9 and recombinant adeno-associated virus serotype 6 for the study of B cell therapies. The method is relatively simple and allows efficient gene editing of rhesus macaque B cells. The method allows the testing of…

Continue Reading Gene Editing of Primary Rhesus Macaque B Cells

2023-04-25 | NDAQ:TGTX | Press Release

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) annual meeting. Links to…

Continue Reading 2023-04-25 | NDAQ:TGTX | Press Release

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). CAS  PubMed  PubMed Central  Google Scholar  Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017). CAS  PubMed  PubMed…

Continue Reading Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Possible frequent multiple mitochondrial DNA copies in a single nucleoid in HeLa cells

Cells Human cervix epitheloid carcinoma HeLa cells (ECACC 93021013; RRID:CVCL_0030) were cultured at 37 °C in Dulbecco′s Modified Eagle′s Medium (DMEM) with 3 mM glutamine, 10% (v/v) fetal calf serum (FCS), 10 mM HEPES, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 5 mM glucose in humidified air with 5% CO2. Human osteosarcoma 143B cells were purchased…

Continue Reading Possible frequent multiple mitochondrial DNA copies in a single nucleoid in HeLa cells

Aridis Provides Corporate Update | India Shorts

LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments. The Company received written notice from MedImmune Limited (“MedImmune”) terminating a certain license covering AR-320, a product candidate currently being evaluated for…

Continue Reading Aridis Provides Corporate Update | India Shorts

Signet ring cell-like diffuse large B-cell lymphoma involving the breast: a case report | BMC Women’s Health

DLBCL is a high-grade lymphoma and the most common type of NHL [4]. DLBCL is highly aggressive, and patients usually present with rapidly expanding lymph nodes and systemic symptoms that require immediate treatment [4]. Although most patients present with swollen lymph nodes, approximately 40% of DLBCL cases arise from extranodal…

Continue Reading Signet ring cell-like diffuse large B-cell lymphoma involving the breast: a case report | BMC Women’s Health

DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response

Reagents, consumables, and kits The oligonucleotides used as primers in the asymmetric polymerase chain reaction (aPCR) and as staple strands for the folding of PB NPs, along with the CpG ODN 1018 adjuvant were purchased from Integrated DNA Technologies (IDT). Fluorescently labelled oligonucleotides used in FRET assay, FAM (donor) and…

Continue Reading DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response

Team co-maps proteins and transcriptome in human tissues

Spatial-CITE-seq workflow design and application to diverse mouse tissue types and human tonsil for co-mapping of proteins and whole transcriptome. a, Scheme of spatial-CITE-seq. A cocktail of ADTs is applied to a PFA-fixed tissue section to label a panel of ~200–300 protein markers in situ. Next, a set of DNA…

Continue Reading Team co-maps proteins and transcriptome in human tissues

ADC Therapeutics : Annual Report – Form 6-K

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

Continue Reading ADC Therapeutics : Annual Report – Form 6-K

Iconic Technology Group Bioinformatics (CLIA) Developer – Part time

Role: Bioinformatics (CLIA) Developer Location: Remote 1099 / W2  Part time ( 4-10 hours/ week) Qualification : M.S./PhD in Bioinformatics, Bioengineering, Computer Science or related field with 5+ years of experience required Demonstrated bioinformatics pipeline development supporting multiple NGS applications (WGS/WES, RNA-seq, single cell RNA-seq, data automation from sequencer to…

Continue Reading Iconic Technology Group Bioinformatics (CLIA) Developer – Part time

Antibody Response to Omicron Variant Reduced 8 Months After COVID-19 Vaccination

Antibodies against Omicron BA.1 saw a reduction as time went on post vaccination, according to a study published in The Journal of Infectious Diseases. Researchers found that antibody responses to BA.2 and BA.5 were also reduced. Omicron became the dominant variant of concern in December 2021, with 6 infectious subvariants:…

Continue Reading Antibody Response to Omicron Variant Reduced 8 Months After COVID-19 Vaccination

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI By Investing.com

TG Therapeutics, Inc. (NASDAQ:), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each…

Continue Reading TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI By Investing.com

Donor-Derived Staphylococcus Iugdunensis Endocarditis of Transplanted Heart

FINAL DIAGNOSIS Donor-derived Staphylococcus lugdunensis endocarditis of transplanted heart HISTORY OF PRESENT ILLNESS A 56-year-old man presented as a transfer from an outside hospital with cardiogenic shock from nonischemic cardiomyopathy for consideration of advanced therapies. Prior to presentation, he had been experiencing worsening orthopnea, leg swelling, and dyspnea on exertion….

Continue Reading Donor-Derived Staphylococcus Iugdunensis Endocarditis of Transplanted Heart

Genotyping approach to predict Coa and Cob antigens

Introduction The Colton (CO) blood group system (ISBT No. 015) currently consists of four antigens; a high prevalence antigen, Coa with its antithetical antigen, Cob, and the other high prevalence antigens, Co3 and Co4.1 The CO antigens are carried on red blood cell (RBC) water transporter, aquaporin-1 (AQP1), encoded by…

Continue Reading Genotyping approach to predict Coa and Cob antigens

Iconic Technology Group Bioinformatics (CLIA) Developer

Role: Bioinformatics (CLIA) Developer Location: Remote W2 / C2C is fine Qualification : M.S./PhD in Bioinformatics, Bioengineering, Computer Science or related field with 5+ years of experience required Demonstrated bioinformatics pipeline development supporting multiple NGS applications (WGS/WES, RNA-seq, single cell RNA-seq, data automation from sequencer to reporting (end-to-end solution) etc)…

Continue Reading Iconic Technology Group Bioinformatics (CLIA) Developer

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of … | News

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and…

Continue Reading TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of … | News

Iconic Technology Group Bioinformatics Developer

Job Description Role: Bioinformatics Developer Location: Remote W2 / C2C is fine Qualification : M.S./PhD in Bioinformatics, Bioengineering, Computer Science or related field with 5+ years of experience required Demonstrated bioinformatics pipeline development supporting multiple NGS applications (WGS/WES, RNA-seq, single cell RNA-seq, data automation from sequencer to reporting (end-to-end solution)…

Continue Reading Iconic Technology Group Bioinformatics Developer

Life-threatening pulmonary coinfection with Mycobacterium tuberculosis and Aspergillus lentulus in a diabetic patient diagnosed by metagenome next-generation sequencing | BMC Infectious Diseases

A 79-year-old man was admitted to the cardiology department of our hospital, complaining of a 7-day history of fever, with a temperature up to 39.5 ℃. He denied cough, phlegm, nasal obstruction, pharyngalgia, chest pain, dizziness, or headache. Five days before admission, he was diagnosed with pulmonary infection by chest X-ray…

Continue Reading Life-threatening pulmonary coinfection with Mycobacterium tuberculosis and Aspergillus lentulus in a diabetic patient diagnosed by metagenome next-generation sequencing | BMC Infectious Diseases

Omeros: Worst Has Been Priced In, Initiating With A Buy (NASDAQ:OMER)

AsiaVision Background Omeros Corporation (NASDAQ:OMER) is a commercial small-cap biotech based in the US developing several pipelines targeting complement systems. The most advanced indication is Stem-cell transplant-associated TMA (TA-TMA) that already finished pivotal phase 3, atypical hemolytic uremic syndrome (aHUS) is going through phase 3, and IgA nephropathy is currently…

Continue Reading Omeros: Worst Has Been Priced In, Initiating With A Buy (NASDAQ:OMER)

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals, Inc. LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics…

Continue Reading Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Aridis Reports Top-Line Results of the Phase 3

LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the…

Continue Reading Aridis Reports Top-Line Results of the Phase 3

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Senior Clinical Bioinformatics Scientist – Medical Center, New York, United States

Senior Clinical Bioinformatics Scientist 525626 Medical Center Institute for Genomic Medicine Full Time Grade 104 Job Type: Officer of Administration Bargaining Unit: Regular/Temporary: Regular End Date if Temporary: Hours Per Week: 35 Salary Range:   Position Summary The Precision Genomics Laboratory (PGL), a partnership between the Department of Pathology and…

Continue Reading Senior Clinical Bioinformatics Scientist – Medical Center, New York, United States

An in silico approach to study the role of epitope order in the multi-epitope-based peptide (MEBP) vaccine design

The purpose of a vaccine (MEBPVC in the current context) is to elicit a strong response from the host immune system against a disease (COVID-19) releasing various neutralizing antibodies which continue to stay in the body to protect the host from any repeat infection thenceforth. Toll-like receptors (TLRs) are the…

Continue Reading An in silico approach to study the role of epitope order in the multi-epitope-based peptide (MEBP) vaccine design

A Differential Immune Regulatory Role of EGR2 in B6/lpr Versus Normal B6 Mice.docx

Previous studies have reported that deletion of the transcription factor, early growth response protein 2 (EGR2), in normal C57BL/6 (B6) resulted in the development of lupus-like autoimmune disease. However, increased EGR2 expression has been noted in human and murine lupus, which challenges the notion of the autoimmune suppressive role of…

Continue Reading A Differential Immune Regulatory Role of EGR2 in B6/lpr Versus Normal B6 Mice.docx

COVID-19 vaccines in liver transplant recipients

Introduction Three waves of world wild emerging severe infectious disease pandemics have been presented during this century because of the coronavirus. The severe acute respiratory syndrome (SARS) outbreak in southern China since 2002 has spread to 8096 cases from 29 countries, with a mortality of 9.6%.1 Middle East respiratory syndrome…

Continue Reading COVID-19 vaccines in liver transplant recipients

An Introduction to the Biopharmaceutical Industry – Features

David Gemmell looks at key unit operations, and why chemical engineers are heavily involved in their design, troubleshooting or optimisation TO DATE, the Covid-19 pandemic has taken the lives of over 5.7m1 people and impacted global trade, travel, and the livelihoods of billions. It also sparked a vaccine…

Continue Reading An Introduction to the Biopharmaceutical Industry – Features

Rat Anti-Mouse CD25/IL-2R Antibody

Name Rat Anti-Mouse CD25/IL-2R Antibody (GWB-31929F) Related Product Names Rat Anti-Mouse CD25/IL-2Ra-PE; PMP-22; Protein CD25; SR13 myelin protein; Schwann cell membrane glycoprotein; SAG Cd25; Pmp-22Rat Anti-Mouse CD25/IL-2RPmp22 Gene Symbol IL2RA Gene Fullname Interleukin-2 receptor subunit alpha Gene id 3559 Swissprot ID P01589 Protein Name Interleukin-2 receptor subunit alpha Protein Accession…

Continue Reading Rat Anti-Mouse CD25/IL-2R Antibody

A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors

Cell lines and culture Unless stated otherwise, all tumor target cell lines were sourced from the ATCC via LGC Standards. Human endogenous mesothelin (MSLN)-positive target cell lines H-226 (lung carcinoma, MSLN+, ATCC® CRL-5826™) and AsPC-1 (ATCC CRL-1682), and MSLN-negative Raji control cells (ATCC CCL-86) were cultured in RPMI-1640 Glutamax (Life Technologies,…

Continue Reading A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors

Valine feeding reduces ammonia production through rearrangement of metabolic fluxes in central carbon metabolism of CHO cells

Aghamohseni H, Ohadi K, Spearman M, Krahn N, Moo-Young M, Scharer JM, Butler M, Budman HM (2014) Effects of nutrient levels and average culture pH on the glycosylation pattern of camelid-humanized monoclonal antibody. J Biotechnol 186:98–109. doi.org/10.1016/j.jbiotec.2014.05.024 CAS  Article  PubMed  Google Scholar  Altamirano C, Illanes A, Casablancas A, Gámez X,…

Continue Reading Valine feeding reduces ammonia production through rearrangement of metabolic fluxes in central carbon metabolism of CHO cells

IRE combined with toripalimab versus IRE alone for LAPC

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…

Continue Reading IRE combined with toripalimab versus IRE alone for LAPC

Identification of immunodominant Bartonella bacilliformis proteins: a combined in-silico and serology approach

Introduction Carrión’s disease is a vector-borne biphasic illness restricted to the South American Andes, with Peru as the most affected country. 1 Gomes C Pons MJ Del Valle Mendoza J Ruiz J Carrion’s disease: an eradicable illness?. The causative agent, Bartonella bacilliformis, is transmitted to humans by sandflies (Lutzomyia spp)….

Continue Reading Identification of immunodominant Bartonella bacilliformis proteins: a combined in-silico and serology approach